Evommune shows an extremely favorable modeled risk/reward asymmetry typical of a binary biotech setup, but a quality-floor breach from heavy cash burn, a failed momentum gate, and heavy insider selling keep the engine on exit watch.
Thesis pillars
- Extreme Asymmetric Upside Biotech→Stable
- Quality Floor Breach Cash Burn→Stable
- Momentum Gate Failure→Stable
- +2 more pillars — see the Why tab for full reasoning
Evommune, Inc. (EVMN) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $12.36: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 8.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality; Negative price momentum.
Evommune is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, with two lead candidates in Phase 2 development: EVO756 (an oral MRGPRX2 antagonist for chronic spontaneous urticaria and atopic dermatitis) and EVO301 (a long-acting... Read more
Sell if holding. Engine safety override at $12.36: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 8.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.2/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, no SEC red flags, earnings proximity 32d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and clean insider activity. Suitability: speculative.
About Evommune, Inc.
About Evommune, Inc.
Evommune is advancing two Phase 2 clinical programs targeting chronic inflammatory disease: EVO756, an oral small-molecule MRGPRX2 antagonist in Phase 2b trials for chronic spontaneous urticaria (an estimated 3 million U.S. patients) and atopic dermatitis, and EVO301, a long-acting IL-18-binding fusion protein that met its primary endpoint in a February 2026 Phase 2a atopic-dermatitis readout. The company has no approved products and no product revenue, reporting a $68.9 million net loss for 2025 against $216.7 million in cash and investments intended to fund operations through 2028.
Evommune's two lead candidates use distinct mechanisms: EVO756 blocks MRGPRX2, a receptor on mast cells and peripheral sensory neurons implicated in urticaria and atopic dermatitis, while EVO301 combines an IL-18-binding protein with a serum-albumin-binding domain to extend half-life against IL-18-driven inflammation in atopic dermatitis and ulcerative colitis. The company licenses key technology underpinning its pipeline through agreements with Dermira, Maruho, and AprilBio, and expects to owe milestone and royalty payments under those agreements as EVO756 and EVO301 advance. Evommune has no in-house commercial infrastructure and would need to build sales, marketing, and manufacturing capabilities — either directly or through contract development and manufacturing organizations — before any approved product could reach patients. With cash resourced through 2028, the company's near-term catalysts are Phase 2b readouts: CSU data expected in the second quarter of 2026, atopic-dermatitis data in the second half of 2026, and a planned migraine trial initiation in mid-2026.
Show full overview
Evommune's entire near-term value rests on two clinical-stage assets rather than a diversified portfolio: the 10-K flags that incorrect resource allocation decisions, in particular for its most advanced product candidates, EVO756 and EVO301, could materially harm the business, and neither candidate has yet reached a pivotal trial. EVO756's Phase 2b CSU and AD dose-ranging trials read out in 2026, while EVO301's positive Phase 2a AD result must still be replicated in a subcutaneous Phase 2b formulation before any regulatory filing is plausible — meaning both of Evommune's value drivers face a binary clinical read-out within the same 12-to-18 month window, with no commercialized product to cushion a setback in either.
See also: Healthcare · Biotechnology
From Evommune, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-07Recent Developments — Evommune, Inc.
Latest news
- NEWS Top 3 Health Care Stocks That May Rocket Higher In July — benzinga Jul 6, 2026 neutral
- NEWS Morgan Stanley Maintains Overweight on Evommune, Lowers Price Target to $26 — benzinga Jun 30, 2026 positive
- NEWS This AAR Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday — benzinga Jun 30, 2026 neutral
- NEWS HC Wainwright & Co. Downgrades Evommune to Neutral — benzinga Jun 30, 2026 negative
- NEWS 12 Health Care Stocks Moving In Monday's Intraday Session — benzinga Jun 29, 2026 neutral
Generated 2026-07-07T13:21:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMpipelineEVO756 and EVO30110-K Item 1A: 'in particular for our most advanced product candidates, EVO756 and EVO301, our business, financial condition and results of operations could be materially adversely affected'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Volatile — 17.9% daily ATR makes tight stops impractical. Position-size conservatively.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $12.36: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 8.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $11.71. Score 4.2/10, moderate confidence.
Take-profit target: $27.09 (+119.2% upside). Prior stop was $11.71. Stop-loss: $11.71.
Quality below floor (3.0 < 4.0).
Evommune, Inc. trades at a P/E of N/A (forward -4.0). TrendMatrix value score: 5.4/10. Verdict: Sell.
17 analysts cover EVMN with a consensus score of 4.1/5. Average price target: $31.
What does Evommune, Inc. do?Evommune is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, with two...
Evommune is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, with two lead candidates in Phase 2 development: EVO756 (an oral MRGPRX2 antagonist for chronic spontaneous urticaria and atopic dermatitis) and EVO301 (a long-acting IL-18-binding fusion protein for atopic dermatitis and ulcerative colitis, which met its primary endpoint in a Phase 2a AD trial reported in February 2026). The company has generated no product revenue, reported a $68.9 million net loss and $221.1 million accumulated deficit for 2025, and held approximately $216.7 million in